Drugplain

CASPOFUNGIN ACETATE 5 mg/mL

CASPOFUNGIN ACETATE · INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · Sandoz Inc

1 Recall on RecordCurrently in Shortage
Plain English

CASPOFUNGIN ACETATE is a injection, powder, lyophilized, for solution containing caspofungin acetate at 5 mg/mL, taken intravenous. Manufactured by Sandoz Inc.

Key Facts

Brand Name
CASPOFUNGIN ACETATE
Generic Name
CASPOFUNGIN ACETATE
NDC Code (Product)
0781-3421
Manufacturer
Sandoz Inc
Strength
5 mg/mL
Dosage Form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Route
INTRAVENOUS
Marketing Status
Application #
ANDA200833
Marketing Start
09/04/2018

Recall History

1 Recall on Record
Class II09/18/2015

Sentara Enterprises

Lack of Assurance of Sterility: Product sterility cannot be guaranteed.

TerminatedVoluntary: Firm initiated

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

drug ineffective349 reports
off label use87 reports
multiple organ dysfunction syndrome79 reports
death63 reports
pneumonia63 reports
pyrexia62 reports
septic shock62 reports
product use in unapproved indication61 reports
febrile neutropenia57 reports
pathogen resistance56 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

1 INDICATIONS AND USAGE Caspofungin acetate for injection is an echinocandin antifungal indicated in adults and pediatric patients (3 months of age and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients. ( 1 ) Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. ( 1 ) Treatment of esophageal candidiasis. ( 1 ) Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies. ( 1 ) 1.1 Empirical Therapy for Presumed Fungal Infections in Febrile, Neutropenic Patients Caspofungin acetate for injection is indicated as empirical therapy for presumed fungal infections in febrile, neutropenic adult and pediatric patients (3 months of age and older) [see Clinical Studies ( 14.1 , 14.5 )]. 1.2 Treatment of Candidemia and Other Candida Infections Caspofungin acetate for injection is indicated for the treatment of candidemia and the following candida infections: intra-abdominal abscesses, peritonitis, and pleural space infections in adult and pediatric patients (3 months of age and older) [see Clinical Studies ( 14.2 , 14.5 )] . Limitat

Dosage & Administration

2 DOSAGE AND ADMINISTRATION Important Administration Instructions for All Patients ( 2.1 ): Administer by slow intravenous (IV) infusion over approximately 1 hour. Do not administer by IV bolus administration. Do not mix or co-infuse caspofungin acetate for injection with other medications. Do not use diluents containing dextrose (α-D-glucose). Dosage in Adults [18 years of age and older] ( 2.2 ): Administer a single 70 mg loading dose on Day 1, followed by 50 mg once daily for all indications except esophageal candidiasis. For esophageal candidiasis, use 50 mg once daily with no loading dose. Dosage in Pediatric Patients [3 months to 17 years of age] ( 2.3 ): Dosing should be based on the patient's body surface area. For all indications, administer a single 70 mg/m 2 loading dose on Day 1, followed by 50 mg/m 2 once daily thereafter. Maximum loading dose and daily maintenance dose should not exceed 70 mg, regardless of the patient's calculated dose. Dosage Adjustments in Patients with Hepatic Impairment ( 2.4 ): Reduce dosage for adult patients with moderate hepatic impairment (35 mg once daily, with a 70 mg loading dose on Day 1 where appropriate). Dosage Adjustment in Patients R

Contraindications

4 CONTRAINDICATIONS Caspofungin is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to any component of this product [see Adverse Reactions ( 6 )]. Caspofungin is contraindicated in patients with known hypersensitivity to any component of this product. ( 4 )

Drug Interactions

7 DRUG INTERACTIONS Cyclosporine : In two adult clinical studies, cyclosporine (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of caspofungin. Caspofungin did not increase the plasma levels of cyclosporine. There were transient increases in liver ALT and AST when caspofungin and cyclosporine were co-administered. Monitor patients who develop abnormal liver enzymes during concomitant therapy and evaluate the risk/benefit of continuing therapy [see Warnings and Precautions ( 5.2 ) and Clinical Pharmacology ( 12.3 )] . Tacrolimus : For patients receiving caspofungin and tacrolimus, standard monitoring of tacrolimus trough whole blood concentrations and appropriate tacrolimus dosage adjustments are recommended. Inducers of Hepatic CYP Enzymes Rifampin : Rifampin is a potent CYP3A4 inducer and concomitant administration with caspofungin is expected to reduce the plasma concentrations of caspofungin. Therefore, adult patients on rifampin should receive 70 mg of caspofungin daily and pediatric patients on rifampin should receive 70 mg/m 2 of caspofungin daily (not to exceed an actual daily dose of 70 mg) [see Dosage and Administration ( 2.5 ) and Clinical Pharmacology ( 12.3 )].

Adverse Reactions

6 ADVERSE REACTIONS The following serious adverse reactions are discussed in detail in another section of the labeling: Hypersensitivity [see Warnings and Precautions ( 5.1 )] Hepatic Effects [see Warnings and Precautions ( 5.2 )] Elevated Liver Enzymes During Concomitant Use with Cyclosporine [see Warnings and Precautions ( 5.3 )] Adults: Most common adverse reactions (incidence 10% or greater) are diarrhea, pyrexia, ALT/AST increased, blood alkaline phosphatase increased, and blood potassium decreased. ( 6.1 ) Pediatric Patients: Most common adverse reactions (incidence ≥10%) are pyrexia, diarrhea, rash, ALT/AST increased, blood potassium decreased, hypotension, and chills. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals at 1-866-625-1618 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of caspofungin cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice. Clinical Trials Experience in Adults The overall safety of caspofungin was a

Frequently Asked Questions

What is CASPOFUNGIN ACETATE used for?

CASPOFUNGIN ACETATE contains CASPOFUNGIN ACETATE. It is a injection, powder, lyophilized, for solution taken intravenous. Consult your doctor for specific uses.

Is CASPOFUNGIN ACETATE a controlled substance?

CASPOFUNGIN ACETATE is not classified as a controlled substance by the DEA.

What is the generic name for CASPOFUNGIN ACETATE?

The generic name for CASPOFUNGIN ACETATE is CASPOFUNGIN ACETATE. There are 9 other brand versions of CASPOFUNGIN ACETATE.

What is the NDC code for CASPOFUNGIN ACETATE 5 mg/mL?

The NDC (National Drug Code) for CASPOFUNGIN ACETATE 5 mg/mL is 0781-3421, listed by Sandoz Inc.